ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS Jul 1, 2024 07:13PM
ROSEN, A LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS Jun 28, 2024 11:26AM
MRNS INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRN Jun 5, 2024 08:57PM
Marinus Pharmaceuticals Unveils New Brand as the Company Prepares for Commercialization Feb 23, 2021 07:00AM
Marinus Pharma (MRNS) Names Charles Austin to Board Jul 30, 2020 05:55AM
View Older Stories

Jul 29, 2020 04:00PM Marinus Pharmaceuticals Appoints Charles Austin to Board of Directors
Apr 30, 2020 07:30AM Marinus Pharmaceuticals Announces Formation of Scientific Advisory Board
Apr 27, 2020 04:01PM Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 23, 2020 07:30AM Marinus Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 4, 2020
Mar 23, 2020 04:37PM MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Mar 19, 2020 07:30AM Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications
Mar 16, 2020 07:30AM Marinus Pharmaceuticals Provides Business Reports Update and 2019 Financial Results
Feb 25, 2020 07:30AM Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder
Feb 24, 2020 07:30AM Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences
Feb 3, 2020 07:30AM Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting
Feb 3, 2020 07:30AM Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting
Jan 13, 2020 07:35AM Marinus Pharma (MRNS) Provides Business Outlook for 2020
Jan 13, 2020 07:30AM Marinus Provides Business Outlook for 2020
Jan 7, 2020 07:30AM Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference
Dec 13, 2019 04:43PM Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 12, 2019 07:31AM Marinus Pharma (MRNS) Announces Elan Ezickson to Board
Dec 12, 2019 07:30AM Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors
Dec 9, 2019 06:31AM Marinus Pharma (MRNS) Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in TSC
Dec 9, 2019 06:30AM Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex
Dec 9, 2019 06:07AM Marinus Pharma (MRNS) Highlights Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus
Dec 7, 2019 12:01AM Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting
Nov 27, 2019 07:30AM Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting
Nov 8, 2019 04:00PM Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 6, 2019 07:30AM Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results
Oct 29, 2019 07:30AM Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer
Oct 17, 2019 07:32AM Marinus Pharma (MRNS) Highlights Phase 2 Clinical Data on Ganaxolone in Refractory Status Epilepticus
Oct 17, 2019 07:30AM Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting
Sep 27, 2019 04:05PM Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 26, 2019 07:32AM Marinus Pharma (MRNS) Announces Ganaxolone in Phase 2 Refractory Status Epilepticus Trial Met Primary Endpoint
Sep 26, 2019 07:30AM Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
Aug 23, 2019 04:06PM Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 8, 2019 07:30AM Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results
Jul 23, 2019 07:38AM Marinus Pharma (MRNS) Reports Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression
Jul 23, 2019 07:30AM Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression
Jun 19, 2019 04:00PM Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Jun 3, 2019 07:30AM Marinus Pharmaceuticals to Participate at Upcoming Investor Conferences
May 1, 2019 07:30AM Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
Mar 11, 2019 07:30AM Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results
Mar 11, 2019 03:30AM Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results
Mar 6, 2019 07:38AM Marinus Pharma (MRNS) Commences Phase 3 Study in Children with PCDH19-Related Epilepsy
Mar 6, 2019 07:30AM Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
Mar 5, 2019 07:30AM Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference
Feb 26, 2019 09:02AM Marinus Pharma (MRNS) CEO Christopher M. Cashman to Depart
Feb 26, 2019 09:00AM Marinus Announces Leadership Transition
Feb 20, 2019 07:30AM Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference
Feb 5, 2019 04:00PM Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 25, 2019 04:00PM Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 4, 2018 07:34AM Marinus Pharma (MRNS) Phase 2 Data Show L-T Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients
Dec 4, 2018 07:30AM Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients
Nov 19, 2018 07:30AM Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES
View Older Stories